Neonc Technologies CEO Amir Heshmatpour buys $135,619 in shares By Investing.com

Amir F. Heshmatpour, CEO, President, Director, and 10% Owner of NEONC TECHNOLOGIES HOLDINGS, INC. (), purchased 37,000 shares of the company’s common stock on September 11, 2026. The transactions totaled $135,619, with shares acquired at prices ranging from $3.66 to $3.68, representing a weighted average purchase price of $3.6654 per share. The purchase comes as the stock trades near its 52-week low of $3.00, down 26.8% over the past week. According to InvestingPro analysis, NTHI appears undervalued at current levels, with the company’s Fair Value suggesting potential upside—placing it among undervalued opportunities in the market.

Following these transactions, Mr. Heshmatpour directly holds 3,133,000 shares of common stock. This total includes 275,000 shares held by certain members of his immediate family, for which Mr. Heshmatpour disclaims beneficial ownership except to the extent of any pecuniary interest.

Additionally, Mr. Heshmatpour indirectly holds shares through various entities. He holds a proportionate interest in 256,120 shares through HCWG LLC. An additional 550,000 shares are held by KIG LLC, where his spouse is the sole member; Mr. Heshmatpour disclaims beneficial ownership of these shares except for any pecuniary interest. Furthermore, 3,714,020 shares are indirectly held through AFH Holdings & Advisory, LLC, of which Mr. Heshmatpour is the sole member and manager.

In other recent news, NeOnc Technologies Holdings, Inc. announced positive topline results from its Phase 2a study of the intranasal NEO100 for patients with recurrent IDH1-mutant high-grade glioma. The study achieved its primary endpoint, showing a six-month progression-free survival rate of 48.9%, surpassing the pre-specified benchmark of 20% for standard care. Additionally, median overall survival reached 26.09 months, with 86.7% of patients alive at six months. NeOnc Technologies also received approval from the Department of Health – Abu Dhabi for Investigational New Drug status for both NEO100 and NEO212, enabling further trials in adults and potentially in pediatric patients. The NEO212 trial received its first international regulatory clearance following the completion of Phase 1 clinical evaluation. Furthermore, NeOnc received written feedback from the U.S. Food and Drug Administration regarding manufacturing requirements for NEO212, which led to the cancellation of a planned meeting as the responses were deemed clear. The company held an investor call to discuss the Phase 2a NEO100-01 results, although no detailed financial data or study specifics were disclosed.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.